{"title":"摘要:OT-13-07:通过自体T细胞表达嵌合抗原受体,特异性表达MUC1裂解形式(MUC1*)的huMNC2-CAR44,对晚期MUC1*阳性乳腺癌进行过继免疫治疗的I期研究","authors":"J. Specht, D. Maloney, C. Yeung, Q. Wu, C. Bamdad","doi":"10.1158/1538-7445.sabcs20-ot-13-07","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":342683,"journal":{"name":"Ongoing Clinical Trials Abstracts","volume":"75 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract OT-13-07: Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)\",\"authors\":\"J. Specht, D. Maloney, C. Yeung, Q. Wu, C. Bamdad\",\"doi\":\"10.1158/1538-7445.sabcs20-ot-13-07\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":342683,\"journal\":{\"name\":\"Ongoing Clinical Trials Abstracts\",\"volume\":\"75 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ongoing Clinical Trials Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.sabcs20-ot-13-07\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ongoing Clinical Trials Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.sabcs20-ot-13-07","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract OT-13-07: Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)